Hybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease
A Multicenter Observational Study
John D. Puskas, Michael E. Halkos, Joseph J. DeRose, Emilia Bagiella, Marissa A. Miller, Jessica Overbey, Johannes Bonatti, V.S. Srinivas, Mark Vesely, Francis Sutter, Janine Lynch, Katherine Kirkwood, Timothy A. Shapiro, Konstantinos D. Boudoulas, Juan Crestanello, Thomas Gehrig, Peter Smith, Michael Ragosta, Steven J. Hoff, David Zhao, Annetine C. Gelijns, Wilson Y. Szeto, Giora Weisz, Michael Argenziano, Thomas Vassiliades, Henry Liberman, William Matthai and Deborah D. Ascheim
Multicenter HCR Study: MACCE-Free Survival at End of Study Follow-Up
In this first multicenter observational study of hybrid coronary revascularization (HCR) and multivessel percutaneous coronary intervention (PCI) for patients with hybrid-eligible coronary anatomy, risk-adjusted major adverse cardiovascular and cerebrovascular events (MACCE) rates were similar between groups through 12 months of follow-up. During longer follow-up, at 18 months, MACCE-free survival curves for HCR versus PCI began to diverge, with increasing MACCE in the multivessel PCI group. DES = drug-eluting stent(s).